These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36959867)

  • 21. Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Humbert M; Farber HW; Ghofrani HA; Benza RL; Busse D; Meier C; Hoeper MM
    Eur Respir J; 2019 Jun; 53(6):. PubMed ID: 30923187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis.
    Rosenkranz S; Pausch C; Coghlan JG; Huscher D; Pittrow D; Grünig E; Staehler G; Vizza CD; Gall H; Distler O; Delcroix M; Ghofrani HA; Ewert R; Kabitz HJ; Skowasch D; Behr J; Milger K; Halank M; Wilkens H; Seyfarth HJ; Held M; Scelsi L; Neurohr C; Vonk-Noordegraaf A; Ulrich S; Klose H; Claussen M; Eisenmann S; Schmidt KH; Remppis BA; Skride A; Jureviciene E; Gumbiene L; Miliauskas S; Löffler-Ragg J; Lange TJ; Olsson KM; Hoeper MM; Opitz C
    J Heart Lung Transplant; 2023 Jan; 42(1):102-114. PubMed ID: 36333206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk stratification in chronic thromboembolic pulmonary hypertension predicts survival.
    Sandqvist A; Kylhammar D; Bartfay SE; Hesselstrand R; Hjalmarsson C; Kavianipour M; Nisell M; Rådegran G; Wikström G; Kjellström B; Söderberg S
    Scand Cardiovasc J; 2021 Feb; 55(1):43-49. PubMed ID: 32586166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk stratification refinements with inclusion of haemodynamic variables at follow-up in patients with pulmonary arterial hypertension.
    Boucly A; Beurnier A; Turquier S; Jevnikar M; de Groote P; Chaouat A; Cheron C; Jaïs X; Picard F; Prévot G; Roche A; Solinas S; Cottin V; Bauer F; Montani D; Humbert M; Savale L; Sitbon O;
    Eur Respir J; 2024 Sep; 64(3):. PubMed ID: 38663975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk stratification in adult and pediatric pulmonary arterial hypertension: A systematic review.
    Lokhorst C; van der Werf S; Berger RMF; Douwes JM
    Front Cardiovasc Med; 2022; 9():1035453. PubMed ID: 36440049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognosis in Hispanic patient population with pulmonary arterial hypertension: An application of common risk stratification models.
    Fadah K; Cruz Rodriguez JB; Alkhateeb H; Mukherjee D; Garcia H; Schuller D; Mohammad KO; Sahay S; Nickel NP
    Pulm Circ; 2023 Apr; 13(2):e12209. PubMed ID: 37020706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting mortality during long-term follow-up in pulmonary arterial hypertension.
    Kylhammar D; Hjalmarsson C; Hesselstrand R; Jansson K; Kavianipour M; Kjellström B; Nisell M; Söderberg S; Rådegran G
    ERJ Open Res; 2021 Apr; 7(2):. PubMed ID: 34084789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The original and two new derivative versions of the COMPERA 2.0 risk assessment model: useful tools for guiding balloon pulmonary angioplasty.
    Zhang Y; Li X; Jin Q; Luo Q; Zhao Q; Yang T; Zeng Q; Yan L; Duan A; Huang Z; Hu M; Xiong C; Zhao Z; Liu Z
    Respir Res; 2022 Nov; 23(1):312. PubMed ID: 36376902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk assessment in patients with functional class II pulmonary arterial hypertension: Comparison of physician gestalt with ESC/ERS and the REVEAL 2.0 risk score.
    Sahay S; Tonelli AR; Selej M; Watson Z; Benza RL
    PLoS One; 2020; 15(11):e0241504. PubMed ID: 33175857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are Guideline-recommended Risk Classification Schemes in Pulmonary Hypertension Adequately Robust to Guide the Real-world Setting?
    Akaslan D; Aslanger E; Ataş H; Kocakaya D; Yıldızeli B; Mutlu B
    Balkan Med J; 2023 May; 40(3):188-196. PubMed ID: 37000114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension.
    Lewis RA; Johns CS; Cogliano M; Capener D; Tubman E; Elliot CA; Charalampopoulos A; Sabroe I; Thompson AAR; Billings CG; Hamilton N; Baster K; Laud PJ; Hickey PM; Middleton J; Armstrong IJ; Hurdman JA; Lawrie A; Rothman AMK; Wild JM; Condliffe R; Swift AJ; Kiely DG
    Am J Respir Crit Care Med; 2020 Feb; 201(4):458-468. PubMed ID: 31647310
    [No Abstract]   [Full Text] [Related]  

  • 32. Toward the Implementation of Optimal Cardiac Magnetic Resonance Risk Stratification in Pulmonary Arterial Hypertension.
    Celant LR; Wessels JN; Marcus JT; Meijboom LJ; Bogaard HJ; de Man FS; Vonk Noordegraaf A
    Chest; 2024 Jan; 165(1):181-191. PubMed ID: 37527773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency, characteristics and risk assessment of pulmonary arterial hypertension with a left heart disease phenotype.
    Toma M; Savonitto G; Lombardi CM; Airò E; Driussi M; Gentile P; Howard L; Moschella M; Di Poi E; Pagnesi M; Monti S; Collini V; D'Angelo L; Vecchiato V; Giannoni A; Adamo M; Barbisan D; Bauleo C; Garascia A; Metra M; Sinagra G; Giudice FL; Stolfo D; Ameri P
    Clin Res Cardiol; 2024 Apr; ():. PubMed ID: 38619580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dart to the target: an alternative bull's eye parametric display for European Society of Cardiology / European Respiratory Society goal-orientated risk reduction strategy in pulmonary arterial hypertension.
    Kaymaz C; Akbal OY; Hakgor A; Tokgoz HC; Tanyeri S
    Pulm Circ; 2018; 8(3):2045894018780522. PubMed ID: 29767575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients.
    Delcroix M; Staehler G; Gall H; Grünig E; Held M; Halank M; Klose H; Vonk-Noordegraaf A; Rosenkranz S; Pepke-Zaba J; Opitz CF; Gibbs JSR; Lange TJ; Tsangaris I; Huscher D; Pittrow D; Olsson KM; Hoeper MM
    Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30337446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes and prognostic factors of decompensated pulmonary hypertension in the intensive care unit.
    Garcia MVF; Souza R; Costa ELV; Fernandes CJCS; Jardim CVP; Caruso P
    Respir Med; 2021 Dec; 190():106685. PubMed ID: 34823189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk assessment in pulmonary hypertension based on routinely measured laboratory parameters.
    Yogeswaran A; Tello K; Lund J; Klose H; Harbaum L; Sommer N; Oqueka T; Hennigs JK; Grimminger F; Seeger W; Ghofrani HA; Richter MJ; Gall H
    J Heart Lung Transplant; 2022 Mar; 41(3):400-410. PubMed ID: 34857454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk stratification in patients with pulmonary arterial hypertension at the time of listing for lung transplantation.
    Vicaire H; Pavec JL; Mercier O; Montani D; Boucly A; Roche A; Pradère P; Dauriat G; Feuillet S; Pichon J; Jevnikar M; Beurnier A; Jaïs X; Fadel E; Sitbon O; Humbert M; Savale L
    J Heart Lung Transplant; 2022 Sep; 41(9):1285-1293. PubMed ID: 35778258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk stratification in pulmonary arterial hypertension.
    Weatherald J; Boucly A; Sitbon O
    Curr Opin Pulm Med; 2018 Sep; 24(5):407-415. PubMed ID: 30004992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-center prognostic validation of the risk assessment of the 2015 ESC/ERS guidelines in patients with pulmonary arterial hypertension in Japan.
    Imai R; Adachi S; Yoshida M; Shimokata S; Nakano Y; Okumura N; Murohara T; Kondo T
    Can J Physiol Pharmacol; 2020 Sep; 98(9):653-658. PubMed ID: 32924564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.